[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100637111":3},{"organization":4,"armGroups":7,"interventions":24,"overallOfficials":10,"centralContacts":45,"locations":51,"responsibleParty":69,"collaborators":10,"id":71,"slug":72,"hasResults":73,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":73,"sex":79,"minAge":10,"maxAge":10,"enrollmentInfo":80,"targetDuration":10,"studyType":83,"phases":10,"briefSummary":84,"conditions":85,"keywords":88,"overallStatus":93,"whyStopped":10,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":103},{"fullName":5,"class":6},"Nanjing First Hospital, Nanjing Medical University","OTHER",[8,14,19],{"label":9,"type":10,"description":11,"interventionNames":12},"Anticoagulation Cohort",null,"Patients receiving standard anticoagulation therapy alone without thrombolysis or mechanical thrombectomy.",[13],"Drug: Anticoagulants",{"label":15,"type":10,"description":16,"interventionNames":17},"Thrombolysis Cohort","Patients receiving systemic thrombolysis or catheter-directed thrombolysis.",[18],"Device: Mechanical Thrombectomy Devices",{"label":20,"type":10,"description":21,"interventionNames":22},"Mechanical Thrombectomy Cohort","Patients undergoing mechanical thrombectomy procedures using percutaneous devices.",[23],"Drug: Thrombolytic Agents",[25,32,38],{"type":26,"name":27,"description":28,"armGroupLabels":29,"otherNames":30},"DRUG","Anticoagulants","Low Molecular Weight Heparin (LMWH), Direct Oral Anticoagulants (DOAC), Unfractionated Heparin (UFH), or Warfarin according to guideline-standard regimens.",[9],[31],"Heparin, Enoxaparin, Rivaroxaban, Apixaban, Dabigatran, Edoxaban, Warfarin",{"type":26,"name":33,"description":34,"armGroupLabels":35,"otherNames":36},"Thrombolytic Agents","Urokinase, Pro-urokinase, Alteplase, or Tenecteplase administered systemically or via catheter.",[20],[37],"tPA, rt-PA, Urokinase, Tenecteplase",{"type":39,"name":40,"description":41,"armGroupLabels":42,"otherNames":43},"DEVICE","Mechanical Thrombectomy Devices","Any FDA\u002FNMPA approved mechanical thrombectomy device (e.g., Indigo, FlowTriever, Acoscream) used for clot removal.",[15],[44],"Indigo Aspiration System, FlowTriever, Acostream",[46],{"name":47,"role":48,"phone":49,"phoneExt":10,"email":50},"he xu Dr, doctor","CONTACT","+86 153 6611 0045","kilogram@163.com",[52],{"facility":53,"status":10,"city":54,"state":55,"zip":56,"country":57,"countryCode":58,"cosmosGeoPoint":59,"geoPoint":64,"contacts":65},"Nanjing First Hospital","Nanjing","Jiangsu","210006","China","CN",{"type":60,"coordinates":61},"Point",[62,63],118.77778,32.06167,{"lat":63,"lon":62},[66],{"name":67,"role":48,"phone":68,"phoneExt":10,"email":50},"Interventional Vascular Department Director, doctor","+86-25-52271000",{"type":70,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100637111","strategy-pe-real-world-treatment-strategies-for-intermediate-high-risk-pulmonary-embolism-100637111",false,"NCT07603700","STRATEGY-PE: Real-World Treatment Strategies for Intermediate-High Risk Pulmonary Embolism","Real-World Comparative Effectiveness and Safety of Anticoagulation, Thrombolysis, and Mechanical Thrombectomy in Intermediate-Risk Acute Pulmonary Embolism: A Multicenter Prospective Cohort Study","STRATEGY-PE","Inclusion Criteria:\n\n* Age unlimited (reflecting real-world population).\n* Symptom duration of acute PE ≤ 14 days.\n* Confirmed acute PE by CTPA involving main or lobar pulmonary arteries.\n* Defined as Intermediate-High Risk PE meeting all of the following:\n* RV\u002FLV ratio ≥ 0.9 (by CT or Echocardiography).\n* Elevated cardiac biomarkers (Troponin \\> 99th percentile or BNP \\> 100 pg\u002FmL).\n* Hemodynamically stable (SBP ≥ 90 mmHg, no vasopressors required).\n* Able to provide informed consent and complete follow-up.\n\nExclusion Criteria:\n\n* Already received thrombolysis or mechanical thrombectomy for the current episode prior to enrollment.\n* Unable to obtain baseline or follow-up CTPA imaging.\n* (Note: Unlike strict RCTs, patients with cancer, renal insufficiency, or advanced age are NOT excluded to ensure real-world representativeness).","ALL",{"count":81,"type":82},1300,"ESTIMATED","OBSERVATIONAL","This study aims to compare the effectiveness and safety of three treatment strategies (Anticoagulation, Thrombolysis, and Mechanical Thrombectomy) for patients with intermediate-high risk acute pulmonary embolism (PE) in a real-world setting. Approximately 1,300 patients will be enrolled across multiple centers in China. Patients will be followed for 90 days to assess mortality, heart function recovery, bleeding risks, and quality of life. The results will help guide personalized treatment decisions and healthcare policy.",[86,87],"Pulmonary Embolism","Venous Thromboembolism",[89,90,91,92],"Acute Pulmonary Embolism","Intermediate-High Risk","Anticoagulation","Thrombolysis","NOT_YET_RECRUITING","2026-05-17",{"date":96,"type":97},"2026-05-22","ACTUAL",{"date":99,"type":82},"2026-06-01",{"date":101,"type":82},"2029-12-31",{"name":5,"class":6},1]